This Week in Psychedelics

Plus how to educate psychoanalysts about psychedelics, and how ibogaine can help people overcome addiction.

November 25, 2022

This Week...

The Finnish Medicines Agency (FIMEA) granted Clairvoyant Therapeutics, a Canadian drug company, permission to study the effects of psychedelic drug therapies for the treatment of alcohol addiction. FIMEA’s approval marks the first time psychedelic drug trials will be carried out in Finland. Here’s more:

What do psychoanalysts need to know about psychedelics? Fluence Trainer Jeffrey Guss, M.D., published a new research article in the peer-reviewed journal Psychoanalytic Dialogues to answer this question. Check it out:

Psychedelic practitioner and ethnobotanist Hattie Wells shared her thoughts with Ethan Nadelmann of the Psychoactive podcast on ibogaine treatments for overcoming addiction. It’s a fascinating conversation worth checking out, particularly as Wells is now working on clinical trials involving ibogaine. You can listen to the podcast in its entirety here:

Did You Know?

Did you know that in their early existence, Africans ingested psilocybin mushrooms to examine the quantum world?

In a 2019 presentation, Kilindi Iyi discusses this in detail, and even makes the case that man’s present-day technology comes up short of adequately traversing these sub-quantum realms without entheogenic technology. Is he right? Check it out and determine for yourself: